Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia Pharma's revenue for the
three
months ended in Mar. 2026 was 円802 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,373 Mil.
RaQualia Pharma's Revenue per Share for the
three
months ended in Mar. 2026 was 円31.41.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円56.32.
Warning Sign:
RaQualia Pharma Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of RaQualia Pharma was -48.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 17.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 23.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, RaQualia Pharma's highest 3-Year average Revenue per Share Growth Rate was 87.90% per year. The lowest was -95.80% per year. And the median was 18.90% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
RaQualia Pharma Revenue Related Terms
RaQualia Pharma Revenue Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RaQualia Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Revenue distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,373 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Revenue of 円1,373 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Revenue too high?
RaQualia Pharma's current Revenue is 円1,373 Mil. Overall, RaQualia Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Revenue compare to VRTX and REGN?
RaQualia Pharma's Revenue of 円1,373 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Revenue is 円1,373 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円311.16, compared to a current price of 円488.00 — trading 56.8% above its estimated fair value. The current Revenue is 円1,373 Mil. RaQualia Pharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Revenue is 円1,373 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円488.00 is trading 56.8% above its estimated GF Value™ of 円311.16.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
Revenue: 円1,373 Mil
GF Value™: 円311.16 vs. price of 円488.00 (56.8% above fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
60GF Score
Get the complete analysis for TSE:4579
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
